AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35437467 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs17580 in dominant, recessive, and codominant models
Number of subjects: 420
Study 35437467 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of genotypes in smoking TB patients
Number of subjects: 420
Study 35437467 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of genotypes in alcoholic TB patients
Number of subjects: 420
Study 35437467 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to cure among 3 genotypes in TB patients
Number of subjects: 420
Study 35437467 — intervention group
Group type: EXPERIMENTAL
Intervention: Type mutation of rs17580 in SERPINA1 gene
Number of subjects: 420
Study 34543285 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg)
Number of subjects: 80
Study 34543285 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cornstarch)
Number of subjects: 80
Study 32585017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil, 25 mg, 3 times a day
Number of subjects: 216
Study 32585017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 34261807 — intervention group
Group type: EXPERIMENTAL
Intervention: Genicular nerve blockade (15 mL 0.25% bupivacaine and 2 mg dexamethasone)
Number of subjects: 40
Study 34261807 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (SHAM group)
Number of subjects: 40
Study 33834250 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewer knowledge treatment (trained interviewers)
Number of subjects: 0
Study 33834250 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 34017029 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse D therapy (60,000 IUs of vitamin D daily for 8 or 10 days depending on BMI)
Number of subjects: 130
Study 34017029 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone (NVD group)
Number of subjects: 130
Study 33208170 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) boost after urgent 3D conformal radiotherapy (3DCRT)
Number of subjects: 7
Study 33208170 — intervention group
Group type: COMPARATOR
Intervention: 3D conformal radiotherapy (3DCRT)
Number of subjects: 7
Study 35379238 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg up to three times daily
Number of subjects: 390
Study 35379238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 33071273 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (R)
Number of subjects: 60
Study 33071273 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise plus leucine supplement (RL)
Number of subjects: 60
Study 33071273 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 60
Study 35786576 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP)
Number of subjects: 30
Study 35786576 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin (PRF)
Number of subjects: 30
Study 35786576 — intervention group
Group type: COMPARATOR
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 30
Study 34133981 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (amoxicillin 500mg) under fasted conditions
Number of subjects: 16
Study 34133981 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (amoxicillin 500mg) under fed conditions
Number of subjects: 16
Study 34133981 — intervention group
Group type: COMPARATOR
Intervention: Reference product (amoxicillin 500mg) under fasted conditions
Number of subjects: 16
Study 34133981 — intervention group
Group type: COMPARATOR
Intervention: Reference product (amoxicillin 500mg) under fed conditions
Number of subjects: 16
Study 32306991 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger tablets (126 tablets for six weeks)
Number of subjects: 70
Study 32306991 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (126 tablets for six weeks)
Number of subjects: 70
Study 35767914 — intervention group
Group type: COMPARATOR
Intervention: Medium-level protein intake group
Number of subjects: 2191
Study 35767914 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level protein intake group
Number of subjects: 2191
Study 35767914 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level protein intake group
Number of subjects: 2191
Study 34215193 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic geriatric assessment added to standard care in the ED
Number of subjects: 432
Study 34215193 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 432
Study 35130946 — intervention group
Group type: EXPERIMENTAL
Intervention: whole cell pertussis (wP) vaccine
Number of subjects: 3000
Study 35130946 — intervention group
Group type: COMPARATOR
Intervention: acellular pertussis (aP) vaccine
Number of subjects: 3000
Study 32290521 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine-Enriched Essential Amino Acids (LEAAs) 4 g thrice daily for four days
Number of subjects: 20
Study 32290521 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo
Number of subjects: 20
Study 32290521 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine-Enriched Essential Amino Acids (LEAAs)
Number of subjects: 20
Study 32533536 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP4345 (3–150 mg multiple oral doses)
Number of subjects: 0
Study 32533536 — intervention group
Group type: COMPARATOR
Intervention: ASP4345 (3–900 mg single oral doses)
Number of subjects: 0
Study 32533536 — intervention group
Group type: COMPARATOR
Intervention: ASP4345 (300 mg single oral dose)
Number of subjects: 0
Study 35135010 — intervention group
Group type: EXPERIMENTAL
Intervention: Health warning label (HWL) on menu
Number of subjects: 96
Study 35135010 — intervention group
Group type: COMPARATOR
Intervention: No health warning label on menu (Control)
Number of subjects: 96
Study 33199274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasinumab 9 mg subcutaneous every 4 weeks (Q4W)
Number of subjects: 563
Study 33199274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasinumab 9 mg intravenous every 8 weeks (Q8W)
Number of subjects: 563
Study 33199274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasinumab 6 mg
Number of subjects: 563
Study 33199274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasinumab 9 mg intravenous
Number of subjects: 563
Study 33199274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 563
Study 32949954 — intervention group
Group type: EXPERIMENTAL
Intervention: Kirtan Kriya meditation (KK)
Number of subjects: 27
Study 32949954 — intervention group
Group type: COMPARATOR
Intervention: Classical music listening (ML)
Number of subjects: 27
Study 34799300 — intervention group
Group type: EXPERIMENTAL
Intervention: Trident™ P2 respirator
Number of subjects: 500
Study 34799300 — intervention group
Group type: COMPARATOR
Intervention: 3M™ Aura™ 9320A + N95 respirator
Number of subjects: 500
Study 34351590 — intervention group
Group type: EXPERIMENTAL
Intervention: Oliceridine (0.1, 0.35, or 0.5 mg)
Number of subjects: 0
Study 34351590 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 0
Study 34351590 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled data of Oliceridine
Number of subjects: 0
Study 34351590 — intervention group
Group type: COMPARATOR
Intervention: Pooled data of Morphine
Number of subjects: 0
Study 36127535 — intervention group
Group type: EXPERIMENTAL
Intervention: Population healthcare (n = 1341)
Number of subjects: 2713
Study 36127535 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 1372)
Number of subjects: 2713
Study 33319930 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate delivery (n=26)
Number of subjects: 56
Study 33319930 — intervention group
Group type: COMPARATOR
Intervention: Temporizing management (n=30)
Number of subjects: 56
Study 32724156 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelaic acid (AA)
Number of subjects: 120
Study 32724156 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyruvic acid (PA)
Number of subjects: 120
Study 33356640 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal exercises integrated with cognitive-behavioural therapy
Number of subjects: 150
Study 33356640 — intervention group
Group type: COMPARATOR
Intervention: General physiotherapy
Number of subjects: 150
Study 34834083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ojeok-San (OJS)
Number of subjects: 20
Study 32686643 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD)
Number of subjects: 30
Study 32686643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 34407037 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized solution 100 U/mL (10 mL)
Number of subjects: 81
Study 34407037 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized solution 10 U/mL (20 mL)
Number of subjects: 81
Study 34407037 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized solution 10 U/mL (30 mL)
Number of subjects: 81
Study 34407037 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase solution
Number of subjects: 81
Study 34407037 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin at 10 U/mL
Number of subjects: 81
Study 35659521 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 16 mg
Number of subjects: 14
Study 35659521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 35435424 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 70
Study 35435424 — intervention group
Group type: COMPARATOR
Intervention: Propofol + Sevoflurane
Number of subjects: 70
Study 32531798 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg every 2 weeks (Q2W)
Number of subjects: 995
Study 32531798 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 400 mg every 2 weeks (Q2W)
Number of subjects: 995
Study 32473887 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloons (DCBs)
Number of subjects: 0
Study 35129852 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 175
Study 35129852 — intervention group
Group type: COMPARATOR
Intervention: Shallow puncture
Number of subjects: 175
Study 35129852 — intervention group
Group type: COMPARATOR
Intervention: Nonacupoint deep puncture
Number of subjects: 175
Study 35129852 — intervention group
Group type: COMPARATOR
Intervention: Nonacupoint shallow puncture
Number of subjects: 175
Study 35129852 — intervention group
Group type: COMPARATOR
Intervention: Nonpenetration acupuncture
Number of subjects: 175
Study 34538851 — intervention group
Group type: EXPERIMENTAL
Intervention: Device B: superpower sound processor with a higher MFO
Number of subjects: 19
Study 34538851 — intervention group
Group type: COMPARATOR
Intervention: Device A: standard sound processor with a lower MFO
Number of subjects: 19
Study 35468321 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide (pooled 10 mg and 15 mg)
Number of subjects: 243
Study 35468321 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 243
Study 35468321 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 243
Study 35468321 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 243
Study 35468321 — intervention group
Group type: COMPARATOR
Intervention: Insulin degludec
Number of subjects: 243
Study 33493170 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to violence in the last year
Number of subjects: 969
Study 33493170 — intervention group
Group type: EXPERIMENTAL
Intervention: Male doctors experiencing abuse
Number of subjects: 969
Study 33493170 — intervention group
Group type: EXPERIMENTAL
Intervention: Female doctors experiencing abuse
Number of subjects: 969
Study 33493170 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctors in governmental medical centers
Number of subjects: 969
Study 33493170 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of abuse reported by doctors in governmental centers
Number of subjects: 969
Study 33493170 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean score of worry regarding workplace violence
Number of subjects: 969
Study 33493170 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief in protection by law
Number of subjects: 969
Study 36045192 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist-guided medication review and communication stimulus
Number of subjects: 609
Study 36045192 — intervention group
Group type: COMPARATOR
Intervention: Usual discharge routines
Number of subjects: 609
Study 35311298 — intervention group
Group type: EXPERIMENTAL
Intervention: Tootling intervention
Number of subjects: 0
Study 33020105 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow during neonatal intubation
Number of subjects: 0
Study 33020105 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no nasal high flow)
Number of subjects: 0
Study 34189841 — intervention group
Group type: COMPARATOR
Intervention: Dulaglutide 1.5 mg
Number of subjects: 1842
Study 34189841 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 3.0 mg
Number of subjects: 1842
Study 34189841 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 4.5 mg
Number of subjects: 1842
Study 32113757 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat CMR
Number of subjects: 32
Study 35698974 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinded n-of-1 trial
Number of subjects: 93
Study 35698974 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded n-of-1 trial
Number of subjects: 93
Study 35698974 — intervention group
Group type: EXPERIMENTAL
Intervention: N-of-1 trials (both unblinded and blinded)
Number of subjects: 93
Study 35698974 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 93
Study 35698974 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between unblinded and blinded arms
Number of subjects: 93
Study 33429736 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 0
Study 33429736 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic hepatectomy (LH)
Number of subjects: 0
Study 36034568 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-assisted group (Smart-doctor)
Number of subjects: 740
Study 36034568 — intervention group
Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 740
Study 32886401 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP(3‐30)NH2 at 200 pmol/kg/min (Clamp D)
Number of subjects: 8
Study 32886401 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP(3‐30)NH2 at 2000 pmol/kg/min (Clamp E)
Number of subjects: 8
Study 32886401 — intervention group
Group type: COMPARATOR
Intervention: Saline (Clamp F)
Number of subjects: 8
Study 35225634 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly sessions of psychotherapy
Number of subjects: 200
Study 35225634 — intervention group
Group type: COMPARATOR
Intervention: Weekly sessions of psychotherapy
Number of subjects: 200
Study 32157684 — intervention group
Group type: EXPERIMENTAL
Intervention: PREPARE plus an easy‐to‐read advance directive (AD)
Number of subjects: 393
Study 32157684 — intervention group
Group type: COMPARATOR
Intervention: AD alone
Number of subjects: 393
Study 34493496 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced therapy (usual care plus measuring skin temperatures at 6-8 plantar sites per foot each day)
Number of subjects: 304
Study 34493496 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced therapy (with hotspot monitoring and activity reduction)
Number of subjects: 304
Study 34493496 — intervention group
Group type: COMPARATOR
Intervention: Usual care (podiatric treatment, education, and therapeutic footwear)
Number of subjects: 304
Study 34493496 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced therapy
Number of subjects: 304
Study 34493496 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 304
Study 33129314 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (booklet, video, home visit, telephone call)
Number of subjects: 234
Study 33129314 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 234
Study 34164675 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligo/Amen + Cal (n=40)
Number of subjects: 76
Study 32443977 — intervention group
Group type: EXPERIMENTAL
Intervention: Suchana program interventions delivered to 40 randomly selected unions annually over 4 years, including normal government nutrition services.
Number of subjects: 157
Study 32443977 — intervention group
Group type: COMPARATOR
Intervention: Control group consisting of the last 40 unions that will not receive the Suchana program interventions.
Number of subjects: 157
Study 35065867 — intervention group
Group type: EXPERIMENTAL
Intervention: Parasternal long (PSL) view
Number of subjects: 6247
Study 35065867 — intervention group
Group type: COMPARATOR
Intervention: Subxiphoid (SX) view
Number of subjects: 6247
Study 32919816 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (100,000 IU monthly)
Number of subjects: 5108
Study 32919816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5108
Study 32919816 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (100,000 IU monthly) in participants with 25(OH)D < 50 nmol/L
Number of subjects: 5108
Study 32919816 — intervention group
Group type: COMPARATOR
Intervention: Placebo in participants with 25(OH)D < 50 nmol/L
Number of subjects: 5108
Study 32730181 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib, Melphalan, and Dexamethasone (BMDex)
Number of subjects: 109
Study 32730181 — intervention group
Group type: COMPARATOR
Intervention: Melphalan and Dexamethasone (MDex)
Number of subjects: 109
Study 34180035 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostemsavir (HIV-1 attachment inhibitor)
Number of subjects: 0
Study 33514049 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of tweets related to panic buying of toilet paper
Number of subjects: 500
Study 35446209 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth home monitoring (part of the REACH randomized clinical trial)
Number of subjects: 148
Study 35446209 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 148
Study 33332453 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal paramedic numbers in resuscitation
Number of subjects: 0
Study 33332453 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35162126 — intervention group
Group type: EXPERIMENTAL
Intervention: Front-of-package warning labels (WLs) with zero, one, or two labels indicating high sugar, sodium, and/or saturated fats
Number of subjects: 449
Study 35162126 — intervention group
Group type: COMPARATOR
Intervention: Unlabeled processed products (Control group)
Number of subjects: 449
Study 33749069 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 1 (two 30-min massages at the effective point of pain for each sole)
Number of subjects: 90
Study 33749069 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 2 (one 30-min massage at the effective point of pain and one 30-min massage at the heel for each sole)
Number of subjects: 90
Study 33749069 — intervention group
Group type: COMPARATOR
Intervention: Control (two 30-minute heel massages)
Number of subjects: 90
Study 33749069 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 33127944 — intervention group
Group type: EXPERIMENTAL
Intervention: ANTERION
Number of subjects: 38
Study 33127944 — intervention group
Group type: COMPARATOR
Intervention: CASIAII
Number of subjects: 38
Study 34547260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor loading dose
Number of subjects: 0
Study 34547260 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous platelet inhibitors
Number of subjects: 0
Study 33754632 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit and feedback (static or dynamic reports)
Number of subjects: 96185
Study 33754632 — intervention group
Group type: COMPARATOR
Intervention: No feedback (control group)
Number of subjects: 96185
Study 32285747 — intervention group
Group type: EXPERIMENTAL
Intervention: High-threat condition (n = 34)
Number of subjects: 69
Study 32285747 — intervention group
Group type: COMPARATOR
Intervention: Low-threat condition (n = 35)
Number of subjects: 69
Study 36171604 — intervention group
Group type: EXPERIMENTAL
Intervention: People-centered advocacy approach
Number of subjects: 400
Study 34289935 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 2,000 IU daily
Number of subjects: 154
Study 34289935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 34305816 — intervention group
Group type: EXPERIMENTAL
Intervention: BAT positive group (activated BAT)
Number of subjects: 160
Study 32880504 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-based therapy (VRBT)
Number of subjects: 28
Study 32880504 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiovascular rehabilitation (CR)
Number of subjects: 28
Study 32880504 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-based therapy (VRBT) after 12 weeks
Number of subjects: 28
Study 32880504 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiovascular rehabilitation (CR) after 12 weeks
Number of subjects: 28
Study 32075583 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic physical intervention (API)
Number of subjects: 42
Study 32075583 — intervention group
Group type: COMPARATOR
Intervention: On-land physical intervention (OLPI)
Number of subjects: 42
Study 32075583 — intervention group
Group type: COMPARATOR
Intervention: Non-physical intervention (NPI)
Number of subjects: 42
Study 35198927 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised nutritional support
Number of subjects: 1389
Study 35198927 — intervention group
Group type: COMPARATOR
Intervention: Usual care nutrition
Number of subjects: 1389
Study 35198927 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum albumin group
Number of subjects: 1389
Study 34579954 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review with follow-up
Number of subjects: 0
Study 34579954 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study 32456525 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZE) + Nutraceutical Compound (NC) containing Monacolin-K, Berberine Hydrochloride, t-Resveratrol, Quercetin, and Chromium (3 months)
Number of subjects: 96